Subinhibitory concentrations of telithromycin, clarithromycin and azithromycin reduce methicillin-resistant Staphylococcus aureus coagulase in vitro and in vivo

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 3, 2008, Pages 647-650

  Yanagihara, Katsunori ^a   Morinaga, Yoshitomo ^a   Nakamura, Shigeki ^a   Seki, Masafumi ^a   Izumikawa, Koichi ^a   Kakeya, Hiroshi ^a   Yamamoto, Yoshihiro ^a   Yamada, Yasuaki ^a   Kamihira, Shimeru ^a   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

MRSA; Pathogenesis; Resistant bacteria

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN DERIVATIVE; COAGULASE; METICILLIN; TELITHROMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG MEGADOSE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUNG INFECTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN;

ANIMALS; AZITHROMYCIN; CLARITHROMYCIN; COAGULASE; ENZYME INHIBITORS; HUMANS; KETOLIDES; MALE; METHICILLIN RESISTANCE; MICE; STAPHYLOCOCCUS AUREUS;

EID: 40049091151     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm507     Document Type: Article

References (12)

1. Bryskier A. Ketolides-telithromycin, an example of a new class of antibacterial agents. Clin Microbiol Infect 2000; 6: 661-9.
2. Mizukane R, Hirakata Y, Kaku M. Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994; 38: 528-33.
3. Lagrou K, Peetermans WE, Jorissen M et al. Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to respiratory epithelial cells in vitro. J Antimicrob Chemother 2000; 46: 717-23.
4. Fukuda Y, Yanagihara K, Higashiyama Y et al. Effects of macrolides against pneumolysin of macrolide-resistant Streptococcus pneumoniae. Eur Respir J 2006; 27: 1020-5.
5. Sawai T, Tomono K, Yanagihara K et al. Role of coagulase in a murine model of hematogenous pulmonary infection by intravenous injection of Staphylococcus aureus enmeshed in agar beads. Infect Immun 1997; 65: 466-71.
6. Yanagihara K, Tashiro M, Fukuda Y et al. Effects of short interfering RNA against methicillin-resistant Staphylococcus aureus coagulase in vitro and in vivo. J Antimicrob Chemother 2006; 57: 122-6.
7. Jorders JZ, Duckworth GJ, Williams RJ. Production of 'virulence factors' by 'epidemic' methicillin-resistant Staphylococcus aureus in vitro. J Med Microbiol 1989; 30: 245-52.
8. Girard D, Finegan SM, Dunne MW et al. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models. J Antimicrob Chemother 2005; 56: 365-71.
9. Suwa T, Yoshida H, Fukushima K et al. Metabolic fate of TE-031(A-56268). (I) Comparative pharmacokinetics of TE-031 and erythromycin stearate in rats and mice. Chemotherapy 36 Suppl 3: 198-204.
10. Jacobs MR, Bajaksouzian S, Appelbaum PC. Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 Gram-positive cocci. J Antimicrob Chemother 2003; 52: 809-12.
11. Gustafsson I, Engstrand L, Cars O. In vitro pharmacodynamic studies of activities of ketolides HMR 3647 (telithromycin) and HMR 3004 against extracellular or intracellular Helicobacter pylori. Antimicrob Agents Chemother 2001; 45: 353-5.
12. Yanagihara K, Kuroki M, Higuchi N et al. Telithromycin inhibits the number of viable bacteria but not lymphocyte accumulation in murine model of chronic respiratory infection. Chemotherapy 2007; 53 10-3.